Amylyx Pharmaceuticals, Inc. ((AMLX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amylyx Pharmaceuticals, Inc. (AMLX) is conducting a Phase 3 study titled A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Avexitide in Participants With Post-Bariatric Hypoglycemia. The study aims to assess the safety and efficacy of avexitide in reducing hypoglycemic events in patients who have undergone Roux-en-Y gastric bypass surgery and suffer from post-bariatric hypoglycemia (PBH). This study holds significant potential for improving patient outcomes in this niche but impactful area.
The intervention being tested is avexitide, a glucagon-like peptide-1 (GLP-1) receptor antagonist, administered via subcutaneous injection. Avexitide is designed to reduce insulin secretion by inhibiting GLP-1 receptor signaling, thus addressing hypoglycemia in PBH patients.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. Participants are randomly assigned to either the avexitide or placebo group in a 3:2 ratio. The primary purpose of the study is treatment, with both participants and investigators blinded to the treatment assignments.
The study began on April 29, 2025, with the primary completion date yet to be announced. The latest update was submitted on August 6, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence market dynamics.
The outcome of this study could significantly impact Amylyx Pharmaceuticals’ stock performance and investor sentiment, given the potential market for effective PBH treatments. The study’s progress is also relevant in the context of competitors developing similar interventions, as success could position Amylyx as a leader in this therapeutic area.
The study is currently ongoing, with further details available on the ClinicalTrials portal.